Compare Modine Manufacturing Company (MOD) vs Summit Therapeutics Inc (SMMT) Price & Performance

Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal and key support at $184. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 exceeding the $1.30 forecast. Recent corporate actions include the completion of a $946.4 million spin-off of its Performance Technologies unit with Gentherm, potentially reshaping its business focus toward thermal management solutions.

The outlook remains supported by strong analyst sentiment with a $331.25 consensus price target and 77% buy ratings, but risks include a high P/E ratio of 67.87 and a projected decline in net profit margin to 4.27% for 2026. The stock offers growth potential from its data center cooling expansion but faces execution risks post-spin-off and competitive pressures in the auto parts sector.

Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.

The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.